A Perspective on Withania somnifera Modulating Antitumor Immunity in Targeting Prostate Cancer. J Immunol Res 2021;2021:9483433
Date
09/07/2021Pubmed ID
34485538Pubmed Central ID
PMC8413038DOI
10.1155/2021/9483433Scopus ID
2-s2.0-85114595038 (requires institutional sign-in at Scopus site) 7 CitationsAbstract
Medicinal plants serve as a lead source of bioactive compounds and have been an integral part of day-to-day life in treating various disease conditions since ancient times. Withaferin A (WFA), a bioactive ingredient of Withania somnifera, has been used for health and medicinal purposes for its adaptogenic, anti-inflammatory, and anticancer properties long before the published literature came into existence. Nearly 25% of pharmaceutical drugs are derived from medicinal plants, classified as dietary supplements. The bioactive compounds in these supplements may serve as chemotherapeutic substances competent to inhibit or reverse the process of carcinogenesis. The role of WFA is appreciated to polarize tumor-suppressive Th1-type immune response inducing natural killer cell activity and may provide an opportunity to manipulate the tumor microenvironment at an early stage to inhibit tumor progression. This article signifies the cumulative information about the role of WFA in modulating antitumor immunity and its potential in targeting prostate cancer.
Author List
Dubey S, Singh M, Nelson A, Karan DAuthors
Dev Karan PhD Associate Professor in the Pathology department at Medical College of WisconsinAriel Nelson MD Assistant Professor in the Medicine department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
AnimalsAntineoplastic Agents, Phytogenic
Disease Models, Animal
Humans
Killer Cells, Natural
Male
Prostate
Prostatic Neoplasms
Th1 Cells
Tumor Microenvironment
Withania
Withanolides
